Jazz Pharmaceuticals receives SMC approval for reimbursement of Sativex
Therapy is for the treatment of spasticity due to multiple sclerosis
Read More
Tag: sativex
GW Pharma begins recruitment for US-based Sativex trial
Trial will evaluate Sativex (nabiximols) for multiple sclerosis spasticity
Read More
GW Pharma regains Sativex rights in UK
The company is taking the reins back from Bayer.
Read More
GW regains US rights to Sativex
GW Pharmaceuticals has reacquired full ownership of US rights to its cannabinoid medicine Sativex following the termination of a previous license agreement with Otsuka.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
